Key Highlights
• The new role carries a fixed end date of March 31, 2027, unless terminated earlier by either party.
• Stephens will forfeit 2027 incentive awards under the revised compensation terms.
• A change of control before the termination date could trigger severance protections under existing agreements.
Integer Holdings (NYSE: ITGR) has restructured a key leadership position, moving an executive into a time-bound special projects role. The medical device manufacturer disclosed the shift as part of a broader adjustment to its senior management team.
Leadership Transition Terms
Jim Stephens, currently President of Cardiac Rhythm Management & Neuromodulation, will assume the title of Executive Vice President, Special Projects. The role is set to conclude on March 31, 2027, unless either Stephens or Integer Holdings opts for earlier termination. The company’s board approved the change through its Compensation and Organization Committee.
Compensation Adjustments
Under the new arrangement, Stephens will not receive short-term or long-term incentive awards for 2027. All other employment terms remain unchanged, including base salary and existing benefits. The adjustment reflects the temporary nature of the position rather than a performance-related decision.
Change of Control Protections
The transition includes specific provisions tied to potential corporate transactions. If a change of control occurs before March 31, 2027, and Stephens remains employed through that date, his departure would be treated as a termination without cause. This aligns with terms outlined in a separate agreement.
Role Scope and Duration
Stephens’ new position focuses on special projects, though Integer Holdings has not detailed the specific initiatives involved. The fixed end date suggests a transitional phase rather than a permanent leadership shift. The company’s filing with the U.S. Securities and Exchange Commission confirms the arrangement was formalized in a letter agreement.
Board Oversight
The Compensation and Organization Committee, which approved the changes, plays a central role in executive compensation and organizational structure at Integer Holdings. The committee’s involvement underscores the strategic nature of the move, though the company has not disclosed broader leadership plans beyond Stephens’ transition.
Investor Considerations
The restructuring does not immediately alter Integer Holdings’ operational leadership but signals a planned evolution in its executive team. Investors may monitor how the special projects role influences the company’s long-term strategy, particularly in its cardiac and neuromodulation segments. The absence of 2027 incentives for Stephens could also impact compensation benchmarks for other executives.
Regulatory Compliance
Integer Holdings filed the details under the Securities Exchange Act of 1934, ensuring transparency for shareholders. The disclosure provides clarity on the terms governing Stephens’ transition, including potential severance scenarios tied to future corporate events.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...